NUVL News and Press, Nuvalent Inc. From 01/04/22

Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Nuvalent (NASDAQ:NUVL): Q3 GAAP EPS of -$0.39 misses by $0.14. Cash, cash equivalents and marketable securities were $302.4 million as of September 30, 2021 Press Release For further details see: Nuvalent EPS misses by $0.14

Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results ARROS-1 Clinical Trial of NVL-520 for the Treatment of Patients with Advanced ROS1-positive NSCLC and Other Solid Tumors is Open for Enrollment Company On-track for Initiation of Clinical Trial of NV...

New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC Nuvalent to present at AACR-NCI-EORTC Molecular Targets Conference Data provided further evidence that NVL-520 and NVL-655 selectively inhibited ROS1 and ALK compared to TRKB, were brai...

A record 62 recent IPOs joined the Russell 2000 small-cap index this month. Here's a look at some of the biotech stocks that just joined: Lyell Immunopharma Lyell Immunopharma (NASDAQ:LYEL), which is developing T cell therapies for solid tumors, had a 25M-share IPO in June expected to net pro...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks flip-flopped between gains and losses Friday to end a volatile week on Wall Street, as investors appeared content to consolidate posit...